

Publications OFSEP au 4 septembre 2019

1.

Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, et al. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. *JAMA Neurol* [Internet]. 2019 Sep 3 [cited 2019 Sep 4];

2.

Vukusic S. La stratification du risque a diminué l'incidence de la LEMP chez les patients traités par natalizumab en France. Poster presented at: JNLF; 2019 Apr 17; Lille, France.

3.

Vukusic S. To use clinical registries in the phase 4 of disease modifying treatment. Oral communication presented at: ECTRIMS; 2019 Sep 11; Stockholm, Sweden.

4.

Thouvenot E, OFSEP, NOMADMUS. Compared CSF biomarker profile of AQP4-Ab, MOG-Ab and double seronegative NMOSD reveals specificities with potential therapeutic implications. Poster presented at: ECTRIMS; 2019 Sep 13; Stockholm, Sweden.

5.

Sharmin S, Lefort M, Vukusic S, OFSEP. Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis. Poster presented at: ECTRIMS; 2019 Sep 13; Stockholm, Sweden.

6.

Roos I. Therapeutic lag in relapsing multiple sclerosis. Poster presented at: ECTRIMS; 2019 Sep 12; Stockholm, Sweden.

7.

Roos I. Determinants of Therapeutic Lag in Relapsing Multiple Sclerosis. Poster presented at: ECTRIMS; 2019 Sep 12; Stockholm, Sweden.

8.

Rollot F. Evaluation des effets cumulés de traitement de fonds sur le risque de handicap chez les patients récurrents-rémitteurs. Poster presented at: JNLF; 2019 Apr 17; Lille, France.

9.

Rollot F. Effectiveness of subcutaneous interferon beta-1a 22/44 µg versus teriflunomide in newly treated patients with multiple sclerosis. A study in a French nationwide cohort of multiple sclerosis: Observatoire Français de la sclérose en plaques (OFSEP). Poster presented at: ECTRIMS; 2019 Sep 12; Stockholm, Sweden.

10.

Poupart J. Efficacité et tolérance du RITUXIMAB prescrit en 1ère ligne dans la prise en charge de la neuromyéélite optique en comparaison aux autres immunosuppresseurs de 1ère ligne : une étude de cohorte rétrospective multicentrique française. Poster presented at: JNLF; 2019 Apr 17; Lille, France.

11.

Mathais S, Moisset X, Taithe F, Labauge P, Pelletier J, Castelnovo G, et al. Incidence of relapses in patients with biotin-treated progressive MS (IPBio-SeP study): intermediate analysis of a French, multicenter study. Poster 3.2-038 presented at: AAN; 2019 May; Philadelphia, USA.

12.

Mathais S, Moisset X, Pereira B, Taithe F, Ciron J, Labauge P, et al. Incidence of relapses in patients with purified high dose biotin-treated progressive multiple sclerosis (IPBio-SeP study): a second intermediate analysis of a French, multicenter study. Poster presented at: ECTRIMS; 2019 Sep 11; Stockholm, Sweden.

13.

Marzullo A, Koccevar G, Stamile C, Durand-Dubief F, Terracina G, Calimeri F, et al. Classification of Multiple Sclerosis Clinical Profiles via Graph Convolutional Neural Networks. *Front Neurosci* [Internet]. 2019 [cited 2019 Jun 12];13.

14.

Makhani N, Lebrun C, Siva A, Narula S, Wassmer E, Brassat D, et al. Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. *Mult Scler J Exp Transl Clin*. 2019 Mar;5(1):2055217319836664.

15.

Leray E. Excess mortality in patients with relapsing-onset multiple sclerosis depends on age rather than disease duration: new insights from an innovative flexible model applied on French OFSEP data ('Observatoire Français de la Sclérose en Plaques'). Oral communication presented at: ECTRIMS; 2019 Sep 13; Stockholm, Sweden.

16.

Lefort M. Effet de l'initiation précoce d'un traitement de fond sur la progression du handicap en sclérose en plaques rémittente : une étude observationnelle des données de l'OFSEP. Poster presented at: JNLF; 2019 Apr 17; Lille, France.

17.

Lebrun-Frenay C, Kantarci O, Siva A, Cara-Dallière C, Louapre C, Durand Dubief F, et al. Radiologically Isolated Syndrome: a 10-year follow-up study to identify factors predicting a clinical event. Communication orale presented at: ECTRIMS; 2019 Sep 11; Stockholm, Sweden.

18.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, et al. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. *Mult Scler*. 2019;25(4):591–600.

19.

Laplaud D-A, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. *Neurology*. 2019 Jul 12;

20.

Kingwell E, Leray E, Zhu F, Petkau J, Edan G, Oger J, et al. Multiple sclerosis: effect of beta interferon treatment on survival. *Brain*. 2019 May 1;142(5):1324–33.

21.

Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, et al. Big multiple sclerosis data network: marginal structural models confirm the long-term impact of DMTs on disability progression. Communication orale presented at: ECTRIMS; 2019 Sep 11; Stockholm, Sweden.

22.

Hillert J, Trojano M, Vukusic S, Magyari M, Butzkueven H, Horakova D, et al. Big Multiple Sclerosis Data – A registry basis for post authorization safety studies (PASS) for multiple sclerosis. Poster presented at: ECTRIMS; 2019 Sep 13; Stockholm, Sweden.

23.

Gros C, De Leener B, Badji A, Maranzano J, Eden D, Dupont SM, et al. Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. *NeuroImage*. 2019 Jan 1;184:901–15.

24.

Glaser A, Trojano M, Iaffaldano P, Vukusic S, Horakova D, Nicholas R, et al. Opportunities and challenges for conducting research on Secondary Progressive Multiple Sclerosis across International Multiple Sclerosis registries through a research network collaboration. Poster presented at: ECTRIMS; 2019 Sep 11; Stockholm, Sweden.

25.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, et al. Multiple sclerosis registries in Europe – An updated mapping survey. *Multiple Sclerosis and Related Disorders*. 2019 Jan 1;27:171–8.

26.

Fedrizzi S, Peyro-Saint-Paul L, Montastruc F, Le Caignec F, Chevanne D, Parienti J-J, et al. Mobile application for adverse drug reaction reporting by patients with relapsing remitting multiple sclerosis

(Vigip-SEP study): a national randomized controlled trial. Oral communication presented at: Société Française de Pharmacologie et de Thérapeutique - Congrès 2019; 2019 Jun; Lyon, France.

27.

Eden D, Gros C, Badji A, Dupont SM, De Leener B, Maranzano J, et al. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. *Brain*. 2019 Mar 1;142(3):633–46.

28.

Derache N, Cuhe J, Calocer F, Branger P, Morello R, Bourre B, et al. Clinical factors of conversion to progressive phase in relapsing-remitting multiple sclerosis patients within 11 years. Poster presented at: ECTRIMS; 2019 Sep 13; Stockholm, Sweden.

29.

David A Laplaud. Comparative effectiveness of teriflunomide versus dimethyl-fumarate in multiple sclerosis. *NEUROLOGY MS ID#: NEUROLOGY/2018/950873*. 2019 Apr 10;

30.

Cotton F. OFSEP, les dernières recommandations [Internet]. Communication orale presented at: 46ème congrès annuel de la société française de neuroradiologie; 2019 Mar 27 [cited 2019 Mar 29]; Paris, France.

31.

Codjia P, Ayrignac X, Carra-Dalliere C, Cohen M, Charif M, Lippi A, et al. Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. *Multiple Sclerosis and Related Disorders*. 2019 Feb 1;28:109–16.

32.

Cobo-Calvo A, Sepúlveda M, Rollet F, Armangué T, Ruiz A, Maillart E, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. *J Neuroinflammation*. 2019 Jul 2;16(1):134.

33.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, et al. Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. *J Neurol*. 2019 Apr;266(4):806–15.

34.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, et al. Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. *J Neurol*. 2019 Apr;266(4):816.

35.

Cobo-Calvo A, Ayrignac X, Kerschen P, Horellou P, Cotton F, Labauge P, et al. Cranial nerve involvement in patients with MOG antibody-associated disease. *Neurol Neuroimmunol Neuroinflamm* [Internet]. 2019 Feb 1 [cited 2019 Apr 11];6(2).

36.

Cobo-Calvo A, D'Hindy H, Collongues N, Ruiz A, Casey R, Vukusic S, et al. MOG-antibodies and multiple sclerosis in adults: a large multicentre cross-sectional study. Poster presented at: ECTRIMS; 2019 Sep 12; Stockholm, Sweden.

37.

Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, et al. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. *Mult Scler*. 2019 May 31;1352458519849511.

38.

Castelnovo G, Papeix C, Lebrun-Frenay C, Levy P, Visy J-M, Coustans M, et al. Long-term effectiveness, safety and tolerability with fingolimod treatment in patients with multiple sclerosis in real-world treatment settings in France: final results of the VIRGILE study. Poster presented at: ECTRIMS; 2019 Sep 13; Stockholm, Sweden.

39.

Casey R. Baseline characteristics of the first patients included in the OFSEP high definition cohort and relationship between quality of life and patients' characteristics. Poster presented at: ECTRIMS; 2019 Sep 11; Stockholm, Sweden.

40.

Callier C. Caractéristique de la cohorte française des pré syndromes radiologiques isolés (PRE RIS). Poster presented at: JNLF; 2019 Apr 17; Lille, France.

41.

Butzkueven H. To design, implement and sustain big data collection in MS. Communication orale presented at: ECTRIMS; 2019 Sep 12; Stockholm, Sweden.

42.

Ayrignac X, Rigau V, Lhermitte B, Vincent T, de Champfleury NM, Carra-Dalliere C, et al. Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. *J Neurol* [Internet]. 2019 Apr 23 [cited 2019 May 27];

43.

Ayrignac X. La GFAP sérique est-elle un biomarqueur d'intérêt dans la SEP? Oral communication presented at: JNLF; 2019 Apr 17; Lille, France.

44.

Ameli R, R.G.Guttmann C, Prieto JC, Rollot F, Palotai M, Vukusic S, et al. Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. *Journal of Neuroradiology* [Internet]. 2019 Apr 11 [cited 2019 Apr 12];

45.

Zeydan B, Gu X, Atkinson EJ, Keegan BM, Weinshenker BG, Tillema J-M, et al. Cervical spinal cord atrophy. *Neurol Neuroimmunol Neuroinflamm* [Internet]. 2018 Jan 22 [cited 2019 Apr 11];5(2).

46.

Zephir H, Puyade M, Gueguen A, Michel L, Terriou L, Dive D, et al. Indications de l'autogreffe dans la sclérose en plaques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) en lien avec la Société francophone de la sclérose en plaques. *Bulletin du Cancer* [Internet]. 2018 Dec 5 [cited 2019 Jan 15];

47.

Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, et al. Did risk stratification modify the incidence of PML in natalizumab-treated MS patients in France? Poster presented at: ECTRIMS; 2018 Oct; Berlin, Germany.

48.

Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud D-A, et al. Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. *Mult Scler*. 2018 Dec 13;1352458518815602.

49.

Spelman T, Magyari M, Sørensen PS, Koch-Henriksen N, Butzkueven H, Vukusic S, et al. Treatment discontinuation in the Big Multiple Sclerosis Data Network: a descriptive analysis. Poster presented at: ECTRIMS; 2018 Oct; Berlin, Germany.

50.

Rollot F, Casey R, Debouverie M, Edan G, Wiertlewski S, Leray E, et al. Assessing the cumulative effects of disease-modifying therapies on the current risk of irreversible disability with relapsing-remitting multiple sclerosis. Poster presented at: ECTRIMS; 2018 Oct; Berlin, Germany.

51.

Perriot S, Mathias A, Perriard G, Canales M, Jonkmans N, Merienne N, et al. Human Induced Pluripotent Stem Cell-Derived Astrocytes Are Differentially Activated by Multiple Sclerosis-Associated Cytokines. *Stem Cell Reports*. 2018 Nov 13;11(5):1199–210.

52.

Ouallet J-C. Controverse : les traitements de fond modifient-ils le passage en forme secondairement progressive ? Synthèse. *Revue Neurologique*. 2018 Apr 1;174:S180–1.

53.

Ouallet DrJ-C. First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: a multicentre study. *Multiple Sclerosis and Related Disorders* [Internet]. 2018 Dec 14 [cited 2019 Jan 15];

54.

Nicolas P, Guerrier O, Benoit A, Durand-Dubief F, Raverot G, Debarbieux S, et al. Unusual neurologic presentation of aseptic abscesses syndrome. *Neurol Neuroimmunol Neuroinflamm*. 2018 Jul;5(4):e469.

55.

Neri VC, Xavier MF, Barros PO, Melo Bento C, Marignier R, Papais Alvarenga R. Case Report: Acute Transverse Myelitis after Zika Virus Infection. *Am J Trop Med Hyg*. 2018 Oct 1;

56.

Mikaeloff Y. Juvenile multiple sclerosis (SOKIDMUS study): evaluation of factors associated with socio-professional performances in adulthood. Poster presented at: ECTRIMS; 2018 Oct; Berlin, Germany.

57.

Makhani N, Lebrun C, Siva A, Narula S, Wassmer E, Brenton JN, et al. Oligoclonal Bands in Spinal Fluid Improve the Specificity of Different MRI Criteria for Dissemination in Space to Predict a First Clinical Event in Children with the Radiologically Isolated Syndrome (S51.002). *Neurology*. 2018 Apr 10;90(15 Supplement):S51.002.

58.

Louapre C. Conventional and advanced MRI in multiple sclerosis. *Revue Neurologique*. 2018 Jun 1;174(6):391–7.

59.

Leray E, Rollot F, Casey R, Roux J, De Seze J, Laplaud D, et al. Quelle utilisation des traitements de fond chez des patients ayant une SEP rémittente en France sur la période 1990–2017 ? Éléments de réponse à partir des données de l'Ofsep. *Revue Neurologique*. 2018;5961(1001):S2–200.

60.

LEFORT M, Edan G, Leray E. Propensity score methods: The study of the effect of β -interferon and glatiramer acetate on multiple sclerosis disability. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE); 2018 Aug 22; Prague, Czech Republic.

61.

Lebrun C, de Seze J. Demyelinating diseases. *Revue Neurologique*. 2018 Jun 1;174(6):355.

62.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, et al. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. *Multiple Sclerosis Journal* [Internet]. 2018 Feb;0(0).

63.

Laplaud D-A, Barbin L, Casey R, Debouverie M, Vukusic S, Labauge P, et al. Efficacité comparée du Teriflunomide et du Dimethyl-Fumarate : une étude observationnelle française multicentrique. *Revue d'Épidémiologie et de Santé Publique*. 2018 Jun 1;66:S201.

64.

Laplaud D-A, Barbin L, Casey R, Debouverie M, Vukusic S, Labauge P, et al. Comparative efficacy of teriflunomide versus dimethyl-fumarate on clinical and MRI outcomes: a two years French multicenter observational study. Oral communication presented at: ECTRIMS; 2018 Oct 11; Berlin, Germany.

65.

Koubiyr I, Deloire M, Coupé P, Dulau C, Besson P, Moroso A, et al. Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome. *Front Neurol* [Internet]. 2018 Oct 11 [cited 2019 Apr 11];9.

66.

Kocevar G, Stamile C, Hannoun S, Roch J-A, Durand-Dubief F, Vukusic S, et al. Weekly follow up of acute lesions in three early multiple sclerosis patients using MR spectroscopy and diffusion. *J Neuroradiol*. 2018 Mar;45(2):108–13.

67.

Jaluent P, Hannoun S, Kocevar G, Rollot F, Durand-Dubief F, Vukusic S, et al. Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus? *Eur J Radiol*. 2018 Aug;105:204–8.

68.

Jaluent P, Pegat A, Grosset-Janin C, Durand-Dubief F, Vukusic S, Marignier R. ‘Myelitis migrans’: A rare cause of treatable myelitis. *Rev Neurol (Paris) [Internet]*. 2018 Aug 21;

69.

Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, et al. The optimal time to start treatment in relapsing remitting multiple sclerosis patients: results from the Big Multiple Sclerosis Data Network. Oral communication presented at: ECTRIMS; 2018 Oct 11; Berlin, Germany.

70.

Hatt M, Laurent B, Ouahabi A, Fayad H, Tan S, Li L, et al. The first MICCAI challenge on PET tumor segmentation. *Medical Image Analysis*. 2018 Feb 1;44:177–95.

71.

Hannoun S, Kocevar G, Durand-Dubief F, Stamile C, Naji A, Cotton F, et al. Evidence of axonal damage in cerebellar peduncles without T2-lesions in multiple sclerosis. *European Journal of Radiology*. 2018 Nov 1;108:114–9.

72.

Hannoun S, Heidelberg D, Hourani R, Nguyen TTT, Brisset J-C, Grand S, et al. Diagnostic value of 3DFLAIR in clinical practice for the detection of infratentorial lesions in multiple sclerosis in regard to dual echo T2 sequences. *European Journal of Radiology*. 2018 May 1;102:146–51.

73.

Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. *JAMA Neurol*. 2018 Apr 1;75(4):478–87.

74.

Guillaume M, Marignier R, Ciron J, Audoin B, Zéphir H, Maillart E, et al. Predictors of outcome after a first attack of Neuromyelitis Optica. Oral communication presented at: ECTRIMS; 2018 Oct 11; Berlin, Germany.

75.

Guégen A, Morvan E, Lecouturier K, Deschamps R, Moulignier A, Bouchareine A, et al. Initial MRI lesion load: a predictor of long-term disability independent of suggestive event. Poster presented at: ECTRIMS; 2018 Oct; Berlin, Germany.

76.

Gros C, De Leener B, Badji A, Maranzano J, Eden D, Dupont SM, et al. Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. *Neuroimage*. 2018 Oct 6;184:901–15.

77.

Gignoux L. Organization of healthcare in multiple sclerosis. *Revue Neurologique*. 2018 Jun 1;174(6):471–4.

78.

Gassama S, Faucheur RL, Grangeon L, Maltête D, Bourre B. A Comparative Analysis Of Diagnosis Delays When Applying The 2017 McDonald Criteria To Patients With Recurring- Remitting Multiple Sclerosis. Poster presented at: ECTRIMS; 2018 Oct; Berlin, Germany.

79.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, et al. Efficacy of rituximab in refractory RRMS. *Mult Scler*. 2018 May 1;

80.

Dugast E, Vogel I, Garcia A, Nicol B, Morille J, Jacq-Foucher M, et al. High-dimensional profiling of single memory CD8+T cells reveals a specific pattern in multiple sclerosis patients. Oral communication presented at: ECTRIMS; 2018 Oct 11; Berlin, Germany.

81.

Derache N, Dufay A, Lebarbey C. Organization of care for multiple sclerosis in France. *Revue Neurologique*. 2018 Jun 1;174(6):475–9.

82.

Defer G, Le Caignec F, Fedrizzi S, Montastruc F, Chevanne D, Parienti J-J, et al. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial. *Trials* [Internet]. 2018 Mar 9 [cited 2019 Apr 11];19.

83.

Defer G, de Seze J, Bouee S, Courouve L, Longin J, Payet M, et al. Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study. *Mult Scler Relat Disord*. 2018 Oct;25:276–81.

84.

Commowick O, Istace A, Kain M, Laurent B, Leray F, Simon M, et al. Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure. *Sci Rep*. 2018 Sep 12;8(1):13650.

85.

Cohen Adad J. Spatial distribution of MS lesions in the cervical spinal cord [Internet]. Présentation orale - 0082. presented at: Joint Annual Meeting ISMRM-ESMRMB / Scientific Session Multiple Sclerosis: Lesions Everywhere; 2018 Jun 18; Paris, France.

86.

Codjia P, Ayrignac X, Carra-Dallière C, Durand-Dubief F, De Seze J, Lebrun-Frenay C, et al. Formes atypiques de sclérose en plaques et autres affections inflammatoires démyélinisantes idiopathiques du système nerveux central : étude nationale sur 88 cas. *Revue Neurologique*. 2018 Apr 1;174:S100–1.

87.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. *Neurology*. 2018 Apr 25;

88.

Cobo-Calvo A, Sepulveda M, Armangué T, Ruiz A, Maillart E, Papeix C, et al. Evaluation of treatment response in adults with relapsing MOG-Ab- associated disease. Oral communication presented at: ECTRIMS; 2018 Oct 12; Berlin, Germany.

89.

Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. *Revue Neurologique*. 2018 Apr;174(4):255–264.

90.

Christine Lebrun-Frénay R Céline Callier, Patrick Vermersch, Caroline Papeix, Emmanuelle Le Page, Françoise Durand-Dubief, Pierre Labauge, OFSEP, SFSEP. Caractéristique de la cohorte française des syndromes radiologiques isolés (RIS). *Revue Neurologique*. 2018;5961(1001):S2–200.

91.

Casey R, Guillemin F, Laplaud D, Leray E, Epstein J, Foucher Y, et al. The OFSEP high definition cohort: to prognosticate the evolution of multiple sclerosis at clinical key steps of the disease. Poster presented at: ECTRIMS; 2018 Oct; Berlin, Germany.

92.

Casey R, Dufay N, Debard N, Brisset J, Brochet B, Clanet M, et al. Observatoire Français de la Sclérose en Plaques : an update. Poster presented at: ECTRIMS; 2018 Oct; Berlin, Germany.

93.

Calocer F, Dejardin O, Droulon K, Launoy G, Defer G. Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients. PLoS ONE. 2018;13(2):e0191646.

94.

Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, Cavillon G, et al. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol. 2018 Apr;265(4):917–25.

95.

Blein C, Chamoux C, Reynaud D, Lepage V. Diversité des prises en charge des patients atteints de sclérose en plaques entre régions françaises. Revue d'Épidémiologie et de Santé Publique. 2018 Nov 1;66(6):385–94.

96.

Bebo BF, Fox RJ, Lee K, Utz U, Thompson AJ. Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Mult Scler. 2018 Apr;24(5):579–86.

97.

Ayrignac X, De Seze J, Vukusic S, Brassat D, Laplaud D, Lebrun-Fréney C, et al. Efficacité et sécurité d'emploi de l'alemtuzumab à 2 ans : retour sur 150 patients français. Revue Neurologique. 2018 Apr 1;174:S155.

98.

Stankoff B. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? Comments. Anti-JCV antibody index in multiple sclerosis care. Revue Neurologique. 2017 Dec 1;173(10):616–8.

99.

Stamile C, Kocevar G, Cotton F, Maes F, Sappey-Marinier D, Van Huffel S. Multiparametric Non-Negative Matrix Factorization for Longitudinal Variations Detection in White-Matter Fiber Bundles. IEEE J Biomed Health Inform. 2017;21(5):1393–402.

100.

Papeix C. Can we discontinue disease-modifying treatments in multiple sclerosis patients? No. Revue Neurologique. 2017 Jan 1;173(1):41–3.

101.

Nicolas P, Marignier R. Neuromielite optique aiguë (malattia di Devic). EMC - Neurologia. 2017 Feb 1;17(1):1–13.

102.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017 Sep;23(10):1377–84.

103.

Marignier R, Cobo Calvo A, Vukusic S. Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol. 2017;30(3):208–15.

104.

Marignier R. Comparative evaluation of successive criteria for neuromyelitis optica. Oral presented at: ECTRIMS; 2017 Oct 26; Paris, France.

105.

Makhani N, Lebrun C, Siva A, Brassat D, Carra Dallière C, de Seze J, et al. Radiologically isolated syndrome in children: Clinical and radiologic outcomes. Neurol Neuroimmunol Neuroinflamm. 2017 Nov;4(6):e395.

106.

Makhani N, Lebrun C, Siva A, Narula S, Wassmer E, Brenton JN, et al. Comparison of MRI Dissemination in Space Criteria for Predicting a First Clinical Event in Children with the Radiologically Isolated Syndrome (S2.001). Neurology. 2017 Apr 18;88(16 Supplement):S2.001.

107.

Kremer S, Boncoeur-Martel M-P, Cotton F. Chapitre 7 - Imagerie des pathologies inflammatoires cérébrales. In: Luciani A, Rahmouni A, editors. *IRM en Pratique Clinique* [Internet]. Content Repository Only!; 2017 [cited 2019 Jan 15]. p. 123–39.

108.

Kalson-Ray S, Edan G, Leray E. An excessive risk of suicide may no longer be a reality for multiple sclerosis patients. *Mult Scler*. 2017 May 1;23(6):864–71.

109.

Ion-Mărgineanu A, Kocevar G, Stamile C, Sima DM, Durand-Dubief F, Van Huffel S, et al. Machine Learning Approach for Classifying Multiple Sclerosis Courses by Combining Clinical Data with Lesion Loads and Magnetic Resonance Metabolic Features. *Front Neurosci*. 2017;11:398.

110.

Ion-Margineanu A, Kocevar G, Stamile C, M. Sima D, Durand-Dubief F, Huffel S, et al. A Comparison of Machine Learning Approaches for Classifying Multiple Sclerosis Courses Using MRSI and Brain Segmentations. In 2017. p. 643–51.

111.

Debard N, Casey R, Vukusic S, investigateurs de l'OFSEP. L'OFSEP : du soin à la recherche, améliorer nos connaissances sur la sclérose en plaques. *La lettre du neurologue* [Internet]. 2017;(3).

112.

Consortium IMSG, Patsopoulos NA, Baranzini SE, Santaniello A, Shoostari P, Cotsapas C, et al. The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility. *bioRxiv*. 2017 Jul 13;143933.

113.

Cobo-Calvo Á, Ruiz A, D'Indy H, Poulat A-L, Carneiro M, Philippe N, et al. MOG antibody-related disorders: common features and uncommon presentations. *J Neurol*. 2017 Sep;264(9):1945–55.

114.

Brochet B, Lebrun-Frénay C, de Sèze J, Zéphir H, Allart E, Audoin B, et al. Chapitre 1 - Signes et symptômes de la sclérose en plaques. In: Brochet B, Lebrun-Frénay C, de Sèze J, Zéphir H, Allart E, Audoin B, et al., editors. *La Sclérose en Plaques - Clinique et Thérapeutique* [Internet]. Elsevier Masson; 2017 [cited 2019 Jan 15]. p. 3–78.

115.

Barros PO, Dias ASO, Kasahara TM, Ornelas AMM, Aguiar RS, Leon SA, et al. Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients. *J Neuroimmunol*. 2017 Jun 15;307:82–90.

116.

Asgari N, Flanagan EP, Fujihara K, Kim HJ, Skejoe HP, Wuerfel J, et al. Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. *Neurol Neuroimmunol Neuroinflamm*. 2017 Jul;4(4):e343.

117.

Androdias G, Bernard E, Biotti D, Collongues N, Durand-Dubief F, Pique J, et al. Multiple sclerosis broke my heart. *Ann Neurol*. 2017 May;81(5):754–8.

118.

Stamile C, Kocevar G, Cotton F, Durand-Dubief F, Hannoun S, Frindel C, et al. A Sensitive and Automatic White Matter Fiber Tracts Model for Longitudinal Analysis of Diffusion Tensor Images in Multiple Sclerosis. *PLoS ONE*. 2016;11(5):e0156405.

119.

Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, et al. Geographical Heterogeneity of Multiple Sclerosis Prevalence in France. *PLoS ONE*. 2016;11(12):e0167556.

120.

Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, et al. Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort. *Neurology - Neuroimmunology & Neuroinflammation*. 2016 Dec;3(6):e297.

121.

Marignier R, Ruiz A, Cavagna S, Nicole A, Watrin C, Touret M, et al. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. *J Neuroinflammation*. 2016 18;13(1):111.

122.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Frangoulis B, et al. Analgésie locorégionale et risque de poussée du post-partum chez les femmes ayant une sclérose en plaques active au cours de la grossesse. *Revue Neurologique*. 2016;172:A96–7.

123.

Kocevar G, Stamile C, Hannoun S, Cotton F, Vukusic S, Durand-Dubief F, et al. Graph Theory-Based Brain Connectivity for Automatic Classification of Multiple Sclerosis Clinical Courses. *Front Neurosci*. 2016;10:478.

124.

Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M, et al. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. *Ann Neurol*. 2016 Feb;79(2):288–94.

125.

Hannoun S, Durand-Dubief F, Roch J-A, Sappey-Marinier D, Cotton F. Tracking successive Wallerian degenerations in a relapsing-remitting multiple sclerosis patient. *J Neuroradiol*. 2016 Oct;43(5):359–61.

126.

Guttmann CR, Rousset M, Roch JA, Hannoun S, Durand-Dubief F, Belaroussi B, et al. Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study. *Mult Scler*. 2016;22(6):761–9.

127.

Cotton F. Observatoire français de la sclérose en plaques, point sur l'imagerie en 2016. *Journal of Neuroradiology*. 2016 Mar 1;43(2):70–1.

128.

Cotton F. Suivi en imagerie par résonance magnétique des patients avec une sclérose en plaques : comment ? *Pratique Neurologique - FMC*. 2016;7(2):153–8.

129.

Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, et al. Efficacy of rituximab in refractory neuromyelitis optica. *Mult Scler*. 2016;22(7):955–9.

130.

Cauteruccio F, Stamile C, Terracina G, Ursino D, Sappey-Marinier D. An automated string-based approach to extracting and characterizing White Matter fiber-bundles. *Comput Biol Med*. 2016 01;77:64–75.

131.

Benoit A, Durand-Dubief F, Amato M-P, Portaccio E, Casey R, Roggerone S, et al. History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort. *Neurology*. 2016 Sep 27;87(13):1360–7.

132.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, et al. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. *Neurology*. 2016 Feb 23;86(8):771–8.

133.

Vukusic S, Durand-Dubief F, Benoit A, Marignier R, Frangoulis B, Confavreux C. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. *Mult Scler*. 2015 Jun;21(7):953–5.

134.

Stamile C, Kocevar G, Cotton F, Hannoun S, Durand-Dubief F, Frindel C, et al. A longitudinal model for variations detection in white matter fiber-bundles. In: 2015 International Conference on Systems, Signals and Image Processing (IWSSIP). 2015. p. 57–60.

135.

Moroso A, Deloire MSA, Ruet A, Ouallet J-C, Casey R, Brochet B. Does cerebrospinal fluid analysis add predictive value to magnetic resonance imaging for long term irreversible disability in patients with early multiple sclerosis? *Journal of the Neurological Sciences*. 2015 Jul 15;354(1):51–5.

136.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, et al. Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. *PLoS ONE*. 2015;10(7):e0132033.

137.

Lebrun C, Forzy G, Collongues N, Cohen M, de Seze J, Hauteceur P. Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. *Revue Neurologique*. 2015 Apr 1;171(4):390–3.

138.

Hannoun S, Roch J-A, Durand-Dubief F, Vukusic S, Sappey-Marinièr D, Guttmann CRG, et al. Weekly multimodal MRI follow-up of two multiple sclerosis active lesions presenting a transient decrease in ADC. *Brain Behav*. 2015 Feb;5(2):e00307.

139.

Cotton F, Hannoun S, Kremer S, Guillaumont J, Dousset V. L'Observatoire français de la sclérose en plaques (OFSEP): établissement d'un protocole commun minimum dans la sclérose en plaques. *Revue Neurologique*. 2015;171:A65–6.

140.

Cotton F, Kremer S, Hannoun S, Vukusic S, Dousset V, Imaging Working Group of the Observatoire Français de la Sclérose en Plaques. OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol. *J Neuroradiol*. 2015 Jun;42(3):133–40.

141.

Caucheteux N, Maarouf A, Genevray M, Leray E, Deschamps R, Chaunu MP, et al. Criteria improving multiple sclerosis diagnosis at the first MRI. *J Neurol*. 2015;262(4):979–87.

142.

Bernard-Valnet R, Liblau RS, Vukusic S, Marignier R. Neuromyelitis optica: a positive appraisal of seronegative cases. *Eur J Neurol*. 2015 Dec;22(12):1511–8, e82-83.

143.

Collongues N, Marignier R, Jacob A, Leite MI, Siva A, Paul F, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. *Mult Scler*. 2014;20(8):1086–94.

144.

Cavallari M, Ceccarelli A, Wang G-Y, Moscufo N, Hannoun S, Matulis CR, et al. Microstructural changes in the striatum and their impact on motor and neuropsychological performance in patients with multiple sclerosis. *PLoS ONE*. 2014;9(7):e101199.

145.

Passante N. TYSEDMUS : suivi observationnel prospectif des patients atteints de sclérose en plaques et traités par TYSABRI® (natalizumab) dans les bases des données EDMUS en France : données finales à cinq ans. *Revue Neurologique*. 2013 Apr 1;169:A227.

146.

Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir H, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. *Neurology*. 2013 Jun 11;80(24):2194–200.

147.

Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. *J Neurol Neurosurg Psychiatry*. 2013 May;84(5):511–6.

148.

Passante N. TYSEDMUS : suivi observationnel prospectif des patients atteints de sclérose en plaques et traités par TYSABRI®(natalizumab) dans les bases des données European Database for Multiple Sclerosis (EDMUS) en France. *Revue Neurologique*. 2012 Apr 1;168:A50–1.

149.

Vukusic S, Debouverie M, Rittleng C, Frangoulis B, Ionescu I, Confavreux C. Grandes tendances dans l'épidémiologie clinique de la sclérose en plaques en France : les temps changent.... *Revue Neurologique*. 2011 Jan 14;167:S6.

150.

Mikaeloff Y, Suissa S, Vallée L, Lubetzki C, Ponsot G, Confavreux C, et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. *J Pediatr*. 2004 Feb;144(2):246–52.

151.

Mikaeloff Y, Adamsbaum C, Husson B, Vallée L, Ponsot G, Confavreux C, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. *Brain*. 2004 Sep;127(Pt 9):1942–7.